Advanced in Transient Global Amnesia

Dr. Stephen S. Flitman

Phoenix, AZ
Advanced
in Transient Global Amnesia
Specialties:Neurology
Accepting New Patients
Offers Telehealth
OverviewInsuranceLocationsClinical Research

Overview

Stephen Flitman is a Neurologist in Phoenix, Arizona. Dr. Flitman and is rated as an Advanced provider by MediFind in the treatment of Transient Global Amnesia. His top areas of expertise are Migraine with Brainstem Aura, Migraine, Cataract Ataxia Deafness, and Spinocerebellar Ataxia Type 10. Dr. Flitman is currently accepting new patients.

His clinical research consists of co-authoring 1 peer reviewed article and participating in 15 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Neurology
Licenses
Psychiatry & Neurology in AZ
Hospital Affiliations
St. Joseph's Hospital And Medical Center
Languages Spoken
English
Gender
Male

Insurance

Please contact the provider to confirm they accept your insurance or if you don't see your insurance listed.

Accepted insurance plans

  •  UnitedHealthcare

Locations

2601 N 3rd St, Suite 125, Phoenix, AZ 85004
602-265-6500

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

15 Clinical Trials

Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer's Disease
Enrollment Status: Active_not_recruiting
Publish Date: January 24, 2025
Intervention Type: Drug
Study Drug: Donanemab
Study Phase: Phase 3
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease
A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Study Evaluating the Safety and Efficacy of Simufilam 100 Mg Tablets in Subjects with Mild-to-Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: Simufilam
Study Phase: Phase 3
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
A Randomized, Placebo-Controlled, Double-Blind Study of ATH-1017 Treatment in Subjects with Mild to Moderate Alzheimer's Disease
Enrollment Status: Completed
Publish Date: November 15, 2024
Intervention Type: Drug
Study Drug: ATH-1017
Study Phase: Phase 2/Phase 3
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of ALZ-801 in Subjects With Early Alzheimer's Disease and APOE4/4 Genotype
Enrollment Status: Completed
Publish Date: August 28, 2024
Intervention Type: Drug
Study Drug: ALZ-801
Study Phase: Phase 3
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
An Open Label, Multicenter, Safety and Pharmacokinetic Study of YKP3089 as Adjunctive Therapy in Subjects With Partial Onset Seizures
Enrollment Status: Completed
Publish Date: May 14, 2024
Intervention Type: Drug
Study Drug: YKP3089
Study Phase: Phase 3
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of LY3451838 in Adults With Treatment-Resistant Migraine
Enrollment Status: Completed
Publish Date: November 28, 2023
Intervention Type: Drug
Study Drug: LY3451838
Study Phase: Phase 2
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
A Multicenter, Randomized, Active-controlled, Double-blind, Double-dummy, Parallel-group Clinical Trial, Investigating the Efficacy, Safety, and Tolerability of Continuous Subcutaneous ND0612 Infusion in Comparison to Oral IR-LD/CD in Subjects With Parkinson's Disease Experiencing Motor Fluctuations (BouNDless)
Enrollment Status: Active_not_recruiting
Publish Date: November 07, 2023
Intervention Type: Drug, Combination product
Study Drugs: ND0612 Solution, Carbidopa, Levodopa
Study Phase: Phase 3
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
GAIN Trial: A Randomized, Double-Blind, Placebo-Controlled Study of COR388 in Subjects With Alzheimer's Disease
Enrollment Status: Completed
Publish Date: February 23, 2023
Intervention Type: Drug
Study Drug: COR388
Study Phase: Phase 2/Phase 3
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Assess the Safety, Tolerability, and Efficacy of BIIB092 in Subjects With Mild Cognitive Impairment Due to Alzheimer's Disease or With Mild Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: November 08, 2022
Intervention Type: Drug
Study Drug: BIIB092
Study Phase: Phase 2
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Aducanumab (BIIB037) in Subjects With Early Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: September 02, 2021
Intervention Type: Drug
Study Phase: Phase 3
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
A Randomized, Double-Blind, Placebo-Controlled and Delayed-Start Study of LY3314814 in Mild Alzheimer's Disease Dementia
Enrollment Status: Terminated
Publish Date: December 03, 2019
Intervention Type: Drug
Study Phase: Phase 3
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
A 24-Month, Phase 3, Multicenter, Placebo-Controlled Study of Efficacy and Safety of Solanezumab Versus Placebo in Prodromal Alzheimer's Disease
Enrollment Status: Terminated
Publish Date: October 10, 2019
Intervention Type: Drug
Study Phase: Phase 3
View 11 Less Clinical Trials

1 Total Publications

Treatment of migraine with occipital nerve blocks using only corticosteroids.
Treatment of migraine with occipital nerve blocks using only corticosteroids.
Journal: Headache
Published: January 05, 2011
Similar Doctors
Expertise in
14
conditions
Dr. Gary N. Reese
Neurology
Expertise in
14
conditions
Dr. Gary N. Reese
Neurology

Honorhealth Ambulatory

3621 N Wells Fargo Ave, 
Scottsdale, AZ 
 (8.5 mi)
855-485-4673
Languages Spoken:
English, Spanish
See accepted insurances
Accepting New Patients
Offers Telehealth

Gary Reese is a Neurologist in Scottsdale, Arizona. Dr. Reese and is rated as an Advanced provider by MediFind in the treatment of Transient Global Amnesia. His top areas of expertise are Seizures, Familial Neurocardiogenic Syncope, Transient Global Amnesia, and Parkinson's Disease. Dr. Reese is currently accepting new patients.

Expertise in
2
conditions
Dr. Shyamala K. Kumar
Neurology
Expertise in
2
conditions
Dr. Shyamala K. Kumar
Neurology
6677 W Thunderbird Rd, Suite D148, 
Glendale, AZ 
 (11.9 mi)
602-843-3811
Languages Spoken:
English, Spanish, Telugu
See accepted insurances
Accepting New Patients

Shyamala Kumar is a Neurologist in Glendale, Arizona. Dr. Kumar and is rated as an Advanced provider by MediFind in the treatment of Transient Global Amnesia. Her top areas of expertise are Transient Global Amnesia, Transient Ischemic Attack (TIA), Stroke, and Memory Loss. Dr. Kumar is currently accepting new patients.

Expertise in
15
conditions
Dr. Marie F. Grill
Neurology
Expertise in
15
conditions
Dr. Marie F. Grill
Neurology

Mayo Clinic Arizona

13400 E Shea Blvd, 
Scottsdale, AZ 
 (17.5 mi)
480-301-8000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Marie Grill is a Neurologist in Scottsdale, Arizona. Dr. Grill and is rated as a Distinguished provider by MediFind in the treatment of Transient Global Amnesia. Her top areas of expertise are Meningitis, West Nile Virus Infection, Encephalitis, Thrombectomy, and Gastrostomy.

Areas of Expertise

When evaluating expertise, MediFind pulls from factors such as the number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

To learn more about how MediFind determines the expertise levels, check out our expert tiers page.

Search for your specific condition
Want to save this doctor for later?
Sign Up
Looking for the best doctor for you?
Start Here
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile